重组人血管内皮素和阿帕替尼联合GP方案治疗晚期肺鳞癌的临床对照研究  

Controlled Clinical Research by Recombinant Human Endostatin(Endostar)and Apatinib Combined with GP Regimen for Advanced Lung Squamous Cell Carcinoma

作　　者：胡珍珍[1] 邹俊韬[1] 夏国金[2] 陈颖兰[1] HU Zhenzhen;ZOU Juntao;XIA Guojin(Jiangxi Cancer Hospital,Nanchang,330029)

机构地区：[1]江西省肿瘤医院,330029 [2]南昌大学第一附属医院,330006

出　　处：《实用癌症杂志》2021年第12期1984-1988,共5页The Practical Journal of Cancer

基　　金：江西省卫健委科技计划资助项目(编号:20185372)。

摘　　要：目的对照研究重组人血管内皮素(恩度)联合GP及阿帕替尼联合GP方案对晚期肺鳞癌的治疗效果及不良反应。方法选取40例晚期肺鳞癌患者作为研究对象,根据随机区组设计法,将所有患者分为观察组和对照组,每组各20例。对照组采用恩度联合GP方案治疗,观察组采用阿帕替尼联合GP方案治疗。比较两组患者近期治疗效果、比较两组患者治疗前后毒副作用发生情况、肿瘤标志物水平变化。结果两组均无CR患者,观察组总有效率、疾病控制率分别为84%和36%,略高于对照组的81%和26%,但无统计学意义(P>0.05);两组的mPFS分别为8.20个月和7.86个月,无统计学差异(P>0.05),观察组与对照组不良反应总发生率分别为55%和50%,无统计学差异(P>0.05)。结论阿帕替尼联合化疗近期疗效与恩度联合化疗类似,不良反应可接受,可作为临床治疗的选择。Objective To evaluate the clinical therapeutic efficacy and toxicity of Endostar and apatinib combined with GP regimen in the treatment of advanced lung squamous cell carcinoma(SCC).Methods 40 patients with advanced squamous cell lung cancer were selected as the subjects.According to the random area group design method,all the patients were divided into the observation group and the control group,each with 20 cases.The control group was treated with Endostar combined with GP regimen.The observation group used apatinib combined with GP regimen.The recent curative effect,the level of tumor markers and the occurrence of toxic and side effects were compared between the 2 groups.Results There were no patients with CR in both groups.The objective response rate(ORR)in the observation group and the control group was 84%and 36%respectively,and the disease control rate(DCR)was 81%and 26%respectively.The short-term efficacy of the observation group seemed to be better than that of the control group,but the difference was not statistically significant.The median PFS was 8.20 months in the observation group and 7.86 months in the control group.The difference was not statistically significant.The overall incidence of adverse reactions was 55%in the observation group and 50%and in the control group,but the difference was not statistically significant(P>O.05).Conclusion The curative effect of observation group is similar to that of control group for advanced lung squamous cell carcinoma.The patients can tolerate the toxic reaction.The combination of apatinib and chemocherapy exhibits the potential to become a new treatment strategy.

关 键 词：重组人血管内皮抑制素 阿帕替尼 肺肿瘤 鳞状细胞癌 抗血管生成药物 化疗 

分 类 号：R734.2[医药卫生—肿瘤]